Reify Health: $220m in Series C funding
Clinical trial technology firm Reify Health has announced an infusion of $220m USD in Series C funding from a group of investors. The latest funding round reportedly brings the company’s total valuation to $2.2b USD.
“What we’re doing, and the future of clinical trials overall, goes beyond decentralized trials,” said Michael Lin, executive chairman of Reify Health. “We need to have a global healthcare system proactively reaching out to patients everywhere and mobilizing the resources necessary to bring trials to them.”